Effective with date of service Feb. 23, 2022, the Medicaid and NC Health Choice programs cover sirolimus protein-bound particles for injectable suspension (albumin-bound).
Effective with date of service Feb. 28, 2022, the Medicaid and NC Health Choice programs cover cabotegravir extended-release injectable suspension, for intramuscular use (Apretude).